Home ›
NPI 1467462432
NPI deactivated
1467462432
1467462432 was paid $713K by Medicaid between Jan 2018 and Dec 2022, across 38 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 35% of everything it billed.
33Billing provider info1467462432
33aNPI1467462432
33bProvider type—
28Total paid$713K
24GClaims26,265
24DCodes billed38
24AFirst – last monthJan 2018 – Dec 2022
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,518 | $126K | |
| 2019 | 4,088 | $86K | |
| 2020 | 5,320 | $207K | |
| 2021 | 7,509 | $203K | |
| 2022 | 4,830 | $91K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 35% | 3,803 | 2,610 | $251K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 10% | 2,470 | 1,562 | $73K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 9.8% | 1,421 | 756 | $70K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 7.5% | 1,841 | 1,488 | $54K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 7.5% | 1,825 | 1,474 | $53K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 5.0% | 1,416 | 1,143 | $36K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.9% | 530 | 345 | $28K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.3% | 864 | 805 | $23K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 3.2% | 1,438 | 1,173 | $23K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.6% | 159 | 144 | $19K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.0% | 1,902 | 1,266 | $14K |
| 88142 | 1.7% | 873 | 634 | $12K |
26 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 1,996 | $11K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.4% | 836 | $10K |
| 80061 | Lipid panel | <1% | 500 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 705 | $6K |
| 80053 | Comprehensive metabolic panel | <1% | 721 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 823 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 687 | $3K |
| 87081 | <1% | 395 | $2K | |
| 80050 | General health panel | <1% | 63 | $1K |
| 87186 | <1% | 143 | $991.15 | |
| 85610 | <1% | 275 | $632.11 | |
| 87340 | <1% | 69 | $593.12 | |
| 86803 | <1% | 46 | $567.85 | |
| 80306 | <1% | 30 | $458.26 | |
| 87070 | <1% | 44 | $427.37 | |
| 88141 | <1% | 13 | $243.43 | |
| 86765 | <1% | 16 | $214.65 | |
| 83655 | <1% | 14 | $187.00 | |
| 82728 | <1% | 14 | $183.48 | |
| 86706 | <1% | 18 | $159.79 | |
| 84439 | <1% | 14 | $150.22 | |
| 81001 | <1% | 87 | $140.99 | |
| 83735 | <1% | 35 | $140.79 | |
| 83550 | <1% | 14 | $116.52 | |
| 88304 | <1% | 19 | $106.17 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 146 | $39.93 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.